Terminated PHASE2 INTERVENTIONAL 1-arm NCT00507637

Blepharospasm Short Interval

Prospective, Open-label, Single-arm, Single-center Trial to Investigate the Tolerability of NT 201 and Quality of Life of Patients in the Treatment of Blepharospasm With Shortened Injection Intervals

Sponsor: Merz Pharmaceuticals GmbH

Conditions Blepharospasm

Interventions NT 201

Updated 5 times since 2017 Last updated: Feb 3, 2012 Started: Aug 31, 2007 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

primary efficacy endpoint not attainable.

Other terminated trials from Merz Pharmaceuticals GmbH

More terminations from Merz Pharmaceuticals GmbH

A PHASE2 clinical study on Blepharospasm, this trial is terminated or withdrawn. The trial is conducted by Merz Pharmaceuticals GmbH and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merz Pharmaceuticals GmbH

Data source: Merz Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bonn, Germany